Topic:
Partnering
Latest Headlines
Latest Headlines
AbbVie, Galapagos extend JAK1 pact into Crohn's disease with $50M carrot
The North Chicago, IL-based drug giant and Belgium's Galapagos have agreed to expand their collaboration on an oral JAK1 inhibitor to include Crohn's disease.
Amgen, Novartis aim to fuel biotech startups in alliances with Atlas Venture
For Amgen and Novartis, investing in the latest fund from Atlas Venture wasn't enough. The Cambridge, MA-based venture firm has struck separate agreements with the two major drugmakers to join forces on biotech startups.
Quintiles signs on to help Merck KGaA right the R&D ship
Amid repeated pipeline struggles and an R&D re-think, Merck KGaA has signed an exclusive deal with the newly public Quintiles, launching a novel collaboration that will give the CRO a seat at the decisionmaking table.
Quintiles joins Merck KGaA's R&D command post in 5-year exclusive
In the pact, investigators at Merck Serono will join hands with experts at Quintiles to shape and guide the company's R&D strategy while the CRO manages trial planning and execution from Phase I through post-marketing studies.
Cash injection raises hopes of diabetes vaccine
An alliance between supermarket chain Tesco and charity Diabetes UK has brought renewed optimism in the pursuit of a vaccine for Type 1 diabetes.
Cempra snags $70M antibiotic pact with Japan's Toyama
Toyama Chemical, a subsidiary of FujiFilm, is paying $10 million upfront and promising up to $60 million more in milestones in exchange for the exclusive commercial rights to the antibiotic solithromycin in Japan.
Vectura joins forces with a new JV biotech in China for respiratory therapies
The U.K.'s Vectura has thrown its dry powder inhaler technology into a newly established Chinese joint venture biotech that is setting out to develop and commercialize new respiratory treatments for a growing Asian market.
Argentine CRO Stat Research taps Datatrak
Stat Research, a Buenos Aires-based CRO, has reached out to eClinical provider Datatrak in an effort to reduce clinical trial costs and accelerate drug development timelines.
GSK signs up with DKSH to tap Hong Kong market
GlaxoSmithKline is turning to market-expansion contractors DKSH to push its antibiotic products in Hong Kong, part of the drugmaker's efforts to cash in on booming Asian demand.
Bristol-Myers Squibb pursues cancer biomarker development deal
Bristol-Myers Squibb will collaborate with Adaptive Biotechnologies to develop immunological biomarkers for cancer, representing another step forward in the development of personalized medicine.
